Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Vomiting 13Nausea 6Neoplasms 5Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Gynecologic Cancer 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Etoposide 10Cisplatin 9Cyclophosphamide 7etoposide phosphate 5Paclitaxel 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5Carboplatin 5fludarabine 4Sirolimus 4Gemcitabine 4pembrolizumab 3fludarabine phosphate 3Sunitinib 3Mesna 3Melphalan 3Filgrastim 3Drug Therapy 3Brentuximab Vedotin 3Bleomycin 3Bevacizumab 3Automobiles 3tremelimumab 2sodium thiosulfate 2pegfilgrastim 2lutetium Lu 177 dotatate 2durvalumab 2Vorinostat 2Stem Cell Transplantation 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Germ Cell and Embryonal × fosaprepitant × Clear all
NCT01736917 2016-05-25

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Hoosier Cancer Research Network

Phase 2 Completed
65 enrolled 14 charts
Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡